单纯性肾囊肿的改良乙醇硬化治疗技术的有效性和安全性评估

注册号:

Registration number:

ChiCTR1900026082 

最近更新日期:

Date of Last Refreshed on:

2019-09-20 19:51:33 

注册时间:

Date of Registration:

2019-09-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

单纯性肾囊肿的改良乙醇硬化治疗技术的有效性和安全性评估

Public title:

Evaluation of efficacy and safety of modified ethanol sclerotherapy for simple renal cyst

注册题目简写:

English Acronym:

研究课题的正式科学名称:

MSCT引导下微创硬化治疗肾囊肿的临床应用研究

Scientific title:

Clinical application of minimally invasive sclerotherapy for renal cyst guided by MSCT

研究课题代号(代码):

Study subject ID:

重庆市垫江县科技局,项目编号 djkjxm2017jsyfysfyy027

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张皓 

研究负责人:

张皓 

Applicant:

Hao Zhang 

Study leader:

Hao Zhang 

申请注册联系人电话:

Applicant telephone:

+86 13896573520

研究负责人电话:

Study leader's
telephone:

+86 13896573520

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

6472988@qq.com

研究负责人电子邮件:

Study leader's E-mail:

6472988@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市垫江县北外街116号

研究负责人通讯地址:

重庆市垫江县北外街116号

Applicant address:

116 Beiwai Street, Dianjiang, Chongqing, China

Study leader's address:

116 Beiwai Street, Dianjiang, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市垫江县人民医院

Applicant's institution:

Dianjiang County People's Hospital of Chongqing

研究负责人所在单位:

重庆市垫江县人民医院

Affiliation of the Leader:

Dianjiang County People's Hospital of Chongqing

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20190612

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

重庆市垫江县人民医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of Dianjiang county people's Hospital of Chongqing

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

朱必敏

Contact Name of the ethic committee:

Bi-Min Zhu

伦理委员会联系地址:

重庆市垫江县北外街116号垫江县人民医院

Contact Address of the ethic committee:

Dianjiang County People's Hospital of Chongqing, 116 Beiwai Street, Dianjiang, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市垫江县人民医院

Primary sponsor:

Dianjiang County People's Hospital of Chongqing

研究实施负责(组长)单位地址:

重庆市垫江县人民医院

Primary sponsor's address:

116 Beiwai Street, Dianjiang, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市垫江县人民医院

具体地址:

垫江县北外街116号

Institution
hospital:

Dianjiang County People's Hospital of Chongqing

Address:

116 Beiwai Street, Dianjiang, Chongqing, China

经费或物资来源:

重庆市垫江县科技局,项目编号 djkjxm2017jsyfysfyy027

Source(s) of funding:

Dianjiang County Science and Technology Bureau of Chongqing, project number djkjxm2017jsyfysfyy027

研究疾病:

单纯性肾囊肿  

Target disease:

Simple Renal Cysts

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨改良乙醇硬化技术治疗单纯性肾囊肿的安全性和有效性。  

Objectives of Study:

To investigate the safety and efficacy of modified technique ethanol sclerotherapy for simple renal cysts.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

肾盂旁囊肿、以前治疗过的囊肿或手术禁忌症患者被排除。

Exclusion criteria:

Patients with peripelvic cysts, previously treated cysts, or procedural contraindications were excluded.

研究实施时间:

Study execute time:

From 2020-02-01 00:00:00 To 2025-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2025-01-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

60

Group:

Experimental group

Sample size:

干预措施:

囊内预注射利多卡因,提高乙醇注射量

干预措施代码:

Intervention:

Preinjection of low-dose intracystic lidocaine; Increase the volume of injected ethanol

Intervention code:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

传统技术

干预措施代码:

Intervention:

Conventional treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chonging

City:

单位(医院):

重庆市垫江县人民医院 

单位级别:

三级甲等综合医院 

Institution
hospital:

Dianjiang people's Hospital of Chongqing

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

视觉模拟疼痛评分

指标类型:

主要指标

Outcome:

Visual analog pain score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

囊肿大小

指标类型:

主要指标

Outcome:

Cyst size

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾脏形态体积

指标类型:

次要指标

Outcome:

Renal morphologic volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

不适用

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

抽签法

Randomization Procedure (please state who generates the random number sequence and by what method):

Lottery method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Open label

Blinding:

Open label

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表、术中记录、随访记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case records, intraoperative records and follow-up records

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2019-09-20 19:51:33